We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: MASLD
MedXY News
EnglishTag

MASLD

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Parental Obesity and the Adult Offspring’s Risk of Metabolic Dysfunction Associated Steatotic Liver Disease: Insights from a UK Birth Cohort Study
GastroenterologyMASLDchildhood adiposity

Parental Obesity and the Adult Offspring’s Risk of Metabolic Dysfunction Associated Steatotic Liver Disease: Insights from a UK Birth Cohort Study

By MedXY|Sep 17, 2026

This UK cohort study reveals that both maternal and paternal obesity before pregnancy significantly increase offspring’s risk of metabolic dysfunction associated steatotic liver disease (MASLD) by age 24, largely mediated by excess ch

New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know
GastroenterologyMASLD
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
metabolic disease

New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know

By MedXY|Sep 15, 2026

An international Delphi panel concludes metabolic dysfunction‑associated steatotic liver disease (MASLD) raises colorectal cancer (CRC) risk. Experts call for earlier, risk‑adapted CRC screening and integrated metabolic care to reduce CRC b

Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD
Diabetes & Endocrinologybariatric surgeryhepatic fibrosis

Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD

By MedXY|Aug 29, 2026

This prospective cohort study compares semaglutide, bariatric surgery, and lifestyle therapy in obese patients with MASLD, demonstrating semaglutide and surgery improve liver steatosis and fibrosis markers better than lifestyle changes alon

Longitudinal Weight Changes in MASLD: Impact on Liver Outcomes and Disease Progression
Diabetes & EndocrinologyobesityMASLD

Longitudinal Weight Changes in MASLD: Impact on Liver Outcomes and Disease Progression

By MedXY|Aug 19, 2026

This study reveals that weight gain exceeding 5% in MASLD patients increases liver-related event risks and liver stiffness, whereas weight loss improves liver stiffness and may reduce adverse outcomes, especially with obesity reversal.

Comparative Effectiveness of Shear Wave Elastography and VCTE in MASLD Risk Stratification: Insights from FIB-4-Based Two-Step Algorithms
Gastroenterologyrisk stratificationMASLD

Comparative Effectiveness of Shear Wave Elastography and VCTE in MASLD Risk Stratification: Insights from FIB-4-Based Two-Step Algorithms

By MedXY|Aug 15, 2026

Shear wave elastography (SWE) shows comparable accuracy to vibration-controlled transient elastography (VCTE) for stratifying liver-related event risk in MASLD patients using FIB-4-based two-step algorithms.

Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD
GastroenterologyMASLDcardiovascular-kidney-metabolic syndrome

Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD

By MedXY|Aug 14, 2026

This article reviews evidence linking cardiovascular-kidney-metabolic syndrome stages to liver fibrosis severity, progression, and liver-related events in metabolic dysfunction-associated steatotic liver disease (MASLD). Higher CKM stages i

Proteomic Insights into MASLD: Sex-Specific Endotypes and Predictive Value for Mortality
Diabetes & EndocrinologyMASLDmetabolic liver disease

Proteomic Insights into MASLD: Sex-Specific Endotypes and Predictive Value for Mortality

By MedXY|Jul 31, 2026

A large-scale proteomic study identified distinct MASLD subtypes influenced by sex differences and developed a four-protein score predicting all-cause mortality, advancing personalized risk assessment beyond traditional liver-centric models

New Obesity Definitions Reclassify Many MASLD Patients but Do Not Improve Liver Risk Prediction
GastroenterologyMASLDliver-related events

New Obesity Definitions Reclassify Many MASLD Patients but Do Not Improve Liver Risk Prediction

By MedXY|Jul 28, 2026

New obesity definitions reclassify many MASLD patients as obese but do not improve prediction of liver-related events over BMI alone, according to a multinational cohort study.

Diabetes & EndocrinologyMASLDpFIB score

pFIB Scores for Pediatric MASLD Fibrosis Linked to Risk of Youth-Onset Type 2 Diabetes in Children with Obesity

By MedXY|Jul 25, 2026

A liver fibrosis risk score (pFIB-6) identifies children with obesity at markedly increased short-term risk of type 2 diabetes, offering a potential tool for early risk stratification.

Polypharmacy Challenges in Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: Navigating Care in a High-Risk Population
Gastroenterologycardiometabolic diseasesMASLD

Polypharmacy Challenges in Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: Navigating Care in a High-Risk Population

By MedXY|Jul 17, 2026

Older adults with MASLD, especially those aged 75 and above, experience a high burden of polypharmacy linked to multimorbidity, necessitating careful medication management to balance disease control and geriatric vulnerabilities.

Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD Study
GastroenterologyGlobal studyliver fibrosis

Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD Study

By MedXY|Jul 16, 2026

The G-MASLD study evaluated the diagnostic accuracy of non-invasive fibrosis tests across 41 countries, revealing regional variability and identifying Agile-3+ and Agile-4 as the most accurate for advanced fibrosis and cirrhosis in MASLD pa

Reclassifying Pediatric NAFLD: Insights from the Steatotic Liver Disease Framework in a Multicenter NASH CRN Study
Gastroenterologydrug-induced liver injuryMASLD

Reclassifying Pediatric NAFLD: Insights from the Steatotic Liver Disease Framework in a Multicenter NASH CRN Study

By MedXY|Jul 15, 2026

A multicenter study reclassifies pediatric NAFLD under the steatotic liver disease framework, revealing most children meet MASLD criteria, while highlighting alcohol and medication-related reclassifications that inform diagnosis and managem

Unraveling the KLF9-NR4A1-p38 MAPK Axis: A Novel Mechanism Linking Intermittent Hypoxia to MASLD in Obstructive Sleep Apnea
Gastroenterologyintermittent hypoxiaKLF9

Unraveling the KLF9-NR4A1-p38 MAPK Axis: A Novel Mechanism Linking Intermittent Hypoxia to MASLD in Obstructive Sleep Apnea

By MedXY|Jul 8, 2026

This study elucidates how KLF9 mediates intermittent hypoxia-induced MASLD by suppressing NR4A1 and p38 MAPK signaling, paving the way for targeted therapies in OSA-associated metabolic liver disease.

Global Insights into MASLD: Predictors of Fibrosis, Clinical Events, and Mortality from the Global-MASLD Study
Diabetes & EndocrinologyfibrosisMASLD

Global Insights into MASLD: Predictors of Fibrosis, Clinical Events, and Mortality from the Global-MASLD Study

By MedXY|Jul 3, 2026

The Global-MASLD study identifies key predictors of advanced fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease, highlighting the prognostic value of noninvasive fibrosis markers across diverse populations.

Decoding Liver Fibrosis in MASLD: AI-Derived Collagen Phenotypes Enhance Molecular and Clinical Insights
Gastroenterologyartificial intelligencecollagen deposition phenotypes

Decoding Liver Fibrosis in MASLD: AI-Derived Collagen Phenotypes Enhance Molecular and Clinical Insights

By MedXY|Jun 25, 2026

This article explores a novel AI framework that identifies distinct collagen deposition patterns in MASLD, offering improved molecular specificity and prognostic value beyond traditional fibrosis assessments.

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds
GastroenterologyALTMASH

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds

By MedXY|Jun 19, 2026

In adults with suspected MASH, 200 IU/day vitamin E lowered ALT as effectively as 400 IU/day and 800 IU/day over 24 weeks, with no short-term safety signal, supporting lower-dose use if vitamin E is chosen.

Adolescent MASLD Plus PCOS Signals a Higher-Risk Cardiometabolic Trajectory Into Adulthood
Diabetes & Endocrinologycardiometabolic riskinsulin resistance

Adolescent MASLD Plus PCOS Signals a Higher-Risk Cardiometabolic Trajectory Into Adulthood

By MedXY|May 28, 2026

In the Raine Study, adolescents with both MASLD and PCOS had a substantially worse cardiometabolic profile by age 27 than peers with either condition alone, highlighting a high-risk subgroup that may warrant earlier metabolic surveillance.

HSP72-PRDX6 Control of PINK1 Ubiquitination Emerges as a New Mitophagy Axis in MASLD
GastroenterologyHSP72MASLD

HSP72-PRDX6 Control of PINK1 Ubiquitination Emerges as a New Mitophagy Axis in MASLD

By MedXY|May 1, 2026

A new Hepatology study identifies an HSP72–PRDX6 pathway that restores PINK1/Parkin mitophagy, reduces hepatic steatosis, and worsens MASLD when disrupted in mice and hepatocytes.

Oral Glucose Absorption Enhanced in Early Metabolic Dysfunction-Associated Steatotic Liver Disease
Diabetes & Endocrinologyglucose absorptioninsulin resistance

Oral Glucose Absorption Enhanced in Early Metabolic Dysfunction-Associated Steatotic Liver Disease

By MedXY|Apr 30, 2026

New research reveals accelerated glucose absorption in early MASLD patients, independent of gastric emptying. This metabolic alteration may drive liver disease progression before hepatic insulin resistance develops.

Early MASLD Is Associated With Enhanced Oral Glucose Absorption Independent of Gastric Emptying
Diabetes & Endocrinologyinsulin resistanceMASLD

Early MASLD Is Associated With Enhanced Oral Glucose Absorption Independent of Gastric Emptying

By MedXY|Apr 30, 2026

Stable-isotope OGTT data suggest that early MASLD is linked to higher oral glucose absorption, independent of gastric emptying, with preserved hepatic insulin suppression but impaired peripheral glucose clearance.

1 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities